Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
4.46
Dollar change
+0.25
Percentage change
5.94
%
IndexRUT P/E- EPS (ttm)-2.09 Insider Own38.25% Shs Outstand144.44M Perf Week0.68%
Market Cap754.14M Forward P/E- EPS next Y-1.55 Insider Trans-0.03% Shs Float104.41M Perf Month-13.23%
Income-323.79M PEG- EPS next Q-0.41 Inst Own60.83% Short Float26.58% Perf Quarter44.81%
Sales0.16M P/S4713.38 EPS this Y21.14% Inst Trans5.07% Short Ratio9.93 Perf Half Y32.74%
Book/sh3.47 P/B1.29 EPS next Y5.90% ROA-35.76% Short Interest27.75M Perf Year-11.33%
Cash/sh2.65 P/C1.68 EPS next 5Y1.00% ROE-42.02% 52W Range2.23 - 6.89 Perf YTD38.94%
Dividend Est.- P/FCF- EPS past 5Y22.18% ROI-48.10% 52W High-35.27% Beta0.80
Dividend TTM- Quick Ratio12.58 Sales past 5Y-24.98% Gross Margin-7505.91% 52W Low100.00% ATR (14)0.36
Dividend Ex-Date- Current Ratio12.58 EPS Y/Y TTM10.07% Oper. Margin-196516.88% RSI (14)47.91 Volatility7.43% 8.23%
Employees361 Debt/Eq0.19 Sales Y/Y TTM-24.70% Profit Margin-202366.25% Recom1.69 Target Price12.08
Option/ShortYes / Yes LT Debt/Eq0.18 EPS Q/Q22.55% Payout- Rel Volume0.68 Prev Close4.21
Sales Surprise-4.55% EPS Surprise-13.13% Sales Q/Q-55.32% EarningsMar 14 AMC Avg Volume2.79M Price4.46
SMA20-7.53% SMA502.98% SMA20015.14% Trades Volume1,897,214 Change5.94%
Date Action Analyst Rating Change Price Target Change
Jan-05-24Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jan-05-24Downgrade Guggenheim Buy → Neutral
Dec-08-23Initiated Citigroup Buy $7
Dec-08-23Initiated Citigroup Buy
Jun-26-23Resumed Oppenheimer Outperform $28
Mar-21-23Initiated Bernstein Mkt Perform $6
Jan-24-23Upgrade JP Morgan Neutral → Overweight $20 → $11
Jan-06-23Upgrade Robert W. Baird Neutral → Outperform $12
Dec-12-22Downgrade BofA Securities Buy → Underperform $24 → $9
Aug-10-22Downgrade Raymond James Outperform → Mkt Perform
Mar-16-24 04:35PM
Mar-15-24 09:32AM
07:04AM
Mar-14-24 08:55PM
05:34PM
05:15PM Loading…
05:15PM
04:15PM
04:05PM
Mar-13-24 12:15PM
Mar-12-24 08:50AM
08:30AM
Mar-05-24 09:55AM
08:30AM
Feb-28-24 08:30AM
Feb-16-24 08:30AM
04:05PM Loading…
Jan-16-24 04:05PM
Jan-12-24 08:34AM
Jan-05-24 12:52PM
08:25AM
08:13AM
Jan-04-24 04:15PM
04:05PM
11:05AM
Jan-03-24 04:05PM
Dec-09-23 12:00PM
Dec-01-23 08:30AM
Nov-24-23 06:40AM
Nov-10-23 12:00PM
Nov-03-23 12:15PM
12:00PM
12:00PM Loading…
12:00PM
10:15AM
Nov-02-23 07:33PM
04:12PM
04:02PM
09:00AM
Oct-30-23 08:30AM
Oct-26-23 08:30AM
Oct-16-23 09:26AM
08:30AM
Sep-27-23 09:09AM
Sep-25-23 08:45AM
Sep-05-23 08:30AM
Aug-29-23 07:30AM
Aug-23-23 12:26PM
Aug-17-23 08:44AM
Aug-14-23 08:30AM
Aug-03-23 11:20AM
Aug-02-23 05:25PM
04:13PM
04:02PM
10:41AM
Jul-26-23 08:30AM
Jun-15-23 09:30AM
Jun-14-23 08:00AM
Jun-09-23 06:25PM
08:02AM
Jun-03-23 09:00AM
Jun-02-23 11:31AM
May-31-23 12:02PM
10:46AM
May-29-23 07:48AM
May-26-23 10:51AM
09:55AM
08:23AM
May-25-23 03:16PM
May-24-23 11:37AM
08:30AM
08:14AM
May-22-23 08:16AM
May-19-23 11:16AM
10:24AM
May-18-23 04:37PM
12:45PM
11:15AM
May-17-23 02:19PM
11:21AM
11:13AM
May-16-23 09:31AM
May-12-23 12:08PM
11:34AM
10:04AM
May-11-23 12:25PM
11:50AM
09:44AM
09:33AM
07:44AM
May-10-23 09:55AM
May-09-23 10:40AM
May-08-23 10:04AM
May-05-23 09:40AM
09:15AM
May-04-23 03:29PM
12:04PM
11:43AM
11:43AM
May-03-23 05:25PM
04:02PM
01:47PM
01:20PM
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parker Geoffrey M.CHIEF FINANCIAL OFFICERJan 30 '24Buy3.60190683819,590Mar 06 09:52 PM
MESSEMER DEBORAH M.DirectorDec 18 '23Sale2.7018,64050,31762,456Dec 20 04:26 PM
Mayo StephenDirectorAug 07 '23Sale4.2910,00042,85525,328Aug 09 04:07 PM